Co‑Diagnostics announced the creation of a new artificial intelligence business unit and appointed Christopher Thurston as Chief Technology & AI Officer. The unit will integrate AI applications into the Co‑Dx Primer Ai platform to accelerate development of proprietary AI‑powered diagnostics and reduce time‑to‑market.
The AI team will focus on internal data and workflow orchestration, Co‑Primers design and optimization, automated test interpretation, real‑time point‑of‑care outcomes, and predictive epidemiological tools. The company will leverage its HIPAA‑compliant cloud platform to support these initiatives.
The move follows a period of declining revenue and net loss. In 2024, Co‑Diagnostics generated $3.9 million in revenue, down from $6.8 million in 2023, and posted a net loss of $37.6 million. The company has invested heavily in research and development of its Co‑Primers technology, which eliminates primer‑dimers and improves multiplexing capabilities.
Management said the new AI unit is intended to address the challenges of scaling the Co‑Dx PCR platform, which remains under regulatory review, and to capitalize on growing demand for rapid, accurate diagnostics. The company also plans to expand its test pipeline in international markets through joint ventures such as CoMira Diagnostics in Saudi Arabia and CoSara Diagnostics in India.
The AI business unit is expected to enhance the company’s ability to develop new tests faster and to provide predictive analytics that could anticipate outbreaks before they occur, positioning Co‑Diagnostics to accelerate commercialization of its Co‑Dx PCR platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.